Nuvectis Pharma Statistics
Total Valuation
NVCT has a market cap or net worth of $119.50 million. The enterprise value is $100.03 million.
| Market Cap | 119.50M |
| Enterprise Value | 100.03M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, before market open.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NVCT has 18.36 million shares outstanding. The number of shares has increased by 12.46% in one year.
| Shares Outstanding | 18.36M |
| Shares Change (YoY) | +12.46% |
| Shares Change (QoQ) | +2.21% |
| Owned by Insiders (%) | 54.13% |
| Owned by Institutions (%) | 16.70% |
| Float | 6.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.52 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.46, with zero debt.
| Current Ratio | 3.46 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -141.60% and return on invested capital (ROIC) is -165.40%.
| Return on Equity (ROE) | -141.60% |
| Return on Assets (ROA) | -104.00% |
| Return on Capital (ROIC) | -165.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.04% in the last 52 weeks. The beta is 0.48, so NVCT's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -60.04% |
| 50-Day Moving Average | 6.61 |
| 200-Day Moving Average | 8.37 |
| Relative Strength Index (RSI) | 48.20 |
| Average Volume (20 Days) | 126,154 |
Short Selling Information
The latest short interest is 1.15 million, so 6.26% of the outstanding shares have been sold short.
| Short Interest | 1.15M |
| Short Previous Month | 1.17M |
| Short % of Shares Out | 6.26% |
| Short % of Float | 18.10% |
| Short Ratio (days to cover) | 13.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.19M |
| Pretax Income | -22.38M |
| Net Income | -22.38M |
| EBITDA | -22.38M |
| EBIT | -22.38M |
| Earnings Per Share (EPS) | -$1.41 |
Balance Sheet
The company has $19.46 million in cash and no debt, giving a net cash position of $19.46 million or $1.06 per share.
| Cash & Cash Equivalents | 19.46M |
| Total Debt | n/a |
| Net Cash | 19.46M |
| Net Cash Per Share | $1.06 |
| Equity (Book Value) | 14.02M |
| Book Value Per Share | 0.76 |
| Working Capital | 14.02M |
Cash Flow
| Operating Cash Flow | -15.54M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.54M |
| FCF Per Share | -$0.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NVCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.46% |
| Shareholder Yield | -12.46% |
| Earnings Yield | -18.73% |
| FCF Yield | -13.00% |
Analyst Forecast
The average price target for NVCT is $21.00, which is 222.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 222.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |